Who is sponsoring NCT06114992?

NCT06114992 is sponsored by Maquet Critical Care AB.

What drugs are being tested in NCT06114992?

Interventions in NCT06114992: Servo-n HFOV modes.

What condition does NCT06114992 study?

NCT06114992 studies Elective HFOV for Respiratory Failure in Neonates/Infants, Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy.

Is NCT06114992 still recruiting?

NCT06114992 is currently recruiting now. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT06114992

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Servo-n HFOV Study: Safety and Performance in Neonates and Infants

Recruiting now Last updated 3 April 2025

What this trial tests

trial testing Servo-n HFOV modes in Elective HFOV for Respiratory Failure in Neonates/Infants in 75 participants. Currently enrolling.

Timeline

15 July 2024

Primary endpoint
30 November 2026

31 December 2026

Quick facts

Lead sponsor	Maquet Critical Care AB
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	75
Start date	15 July 2024
Primary completion	30 November 2026
Estimated completion	31 December 2026
Sites	4 locations across France, Switzerland, Poland

Drugs / interventions tested

Servo-n HFOV modes

Conditions studied

Elective HFOV for Respiratory Failure in Neonates/Infants — all drugs for Elective HFOV for Respiratory Failure in Neonates/Infants →
Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy — all drugs for Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy →

Sponsor

Maquet Critical Care AB

Who can join

Eligibility, any sex, with Elective HFOV for Respiratory Failure in Neonates/Infants or Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06114992 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maquet Critical Care AB
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing